Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663908 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
NCT02663908 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 545 participants.
The verdict
NCT02663908, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
Study Summary
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.
Interventions
- DRUG Degarelix
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2016-04-19 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02663908
The ClinicalTrials.gov registry entry for NCT02663908 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT02663908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02663908 about?
NCT02663908 is a clinical study titled "A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease". The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.
What is the current status of trial NCT02663908?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2016-04-19. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT02663908?
The interventions under investigation include: Degarelix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT02663908?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.